...
首页> 外文期刊>The American Journal of Gastroenterology >Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update.
【24h】

Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update.

机译:Cochrane使用粪便潜血测试(造血术)对结肠直肠癌进行筛查的系统评价:更新。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND AND AIMS: Reducing mortality from colorectal cancer (CRC) may be achieved by the introduction of population-based screening programs. The aim of the systematic review was to update previous research to determine whether screening for CRC using the fecal occult blood test (FOBT) reduces CRC mortality and to consider the benefits, harms, and potential consequences of screening. METHODS: We searched eight electronic databases (Cochrane Library, MEDLINE, EMBASE, CINAHL, PsychINFO, AMED, SIGLE, and HMIC). We identified nine articles describing four randomized controlled trials (RCTs) involving over 320,000 participants with follow-up ranging from 8 to 18 yr. The primary analyses used intention to screen and a secondary analysis adjusted for nonattendance. We calculated the relative risks and risk differences for each trial, and then overall, using fixed and random effects models. RESULTS: Combined results from the four eligible RCTs indicated that screening had a 16% reduction in the relative risk (RR) of CRC mortality (RR 0.84, 95% confidence interval [CI] 0.78-0.90). There was a 15% RR reduction (RR 0.85, 95% CI 0.78-0.92) in CRC mortality for studies that used biennial screening. When adjusted for screening attendance in the individual studies, there was a 25% RR reduction (RR 0.75, 95% CI 0.66-0.84) for those attending at least one round of screening using the FOBT. There was no difference in all-cause mortality (RR 1.00, 95% CI 0.99-1.02) or all-cause mortality excluding CRC (RR 1.01, 95% CI 1.00-1.03). CONCLUSIONS: The present review includes seven new publications and unpublished data concerning CRC screening using FOBT. This review confirms previous research demonstrating that FOBT screening reduces the risk of CRC mortality. The results also indicate that there is no difference in all-cause mortality between the screened and nonscreened populations.
机译:背景和目的:降低大肠癌(CRC)的死亡率可以通过引入基于人群的筛查程序来实现。系统评价的目的是更新以前的研究,以确定使用粪便潜血测试(FOBT)筛查CRC是否会降低CRC死亡率,并考虑筛查的益处,危害和潜在后果。方法:我们搜索了八个电子数据库(Cochrane库,MEDLINE,EMBASE,CINAHL,PsychINFO,AMED,SIGLE和HMIC)。我们确定了9篇文章,描述了4个随机对照试验(RCT),涉及320,000多名参与者,随访时间为8至18年。主要分析使用了意图筛选,而次要分析则针对无人值守进行了调整。我们使用固定效应和随机效应模型计算了每个试验的相对风险和风险差异,然后计算了总体风险。结果:四个符合条件的RCT的合并结果表明,筛查可使CRC死亡的相对风险(RR)降低16%(RR 0.84,95%置信区间[CI] 0.78-0.90)。对于使用两年一次筛查的研究,CRC死亡率降低了15%(RR 0.85,95%CI 0.78-0.92)。调整各个研究中的筛查出席率后,使用FOBT进行至少一轮筛查的受试者的RR降低25%(RR 0.75,95%CI 0.66-0.84)。全因死亡率(RR 1.00,95%CI 0.99-1.02)或除CRC以外的全因死亡率(RR 1.01,95%CI 1.00-1.03)没有差异。结论:本综述包括有关使用FOBT进行CRC筛查的七篇新出版物和未发表的数据。这篇评论证实了先前的研究,表明FOBT筛查可降低CRC死亡率的风险。结果还表明,筛查人群和非筛查人群的全因死亡率没有差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号